These data suggest that direct targeting of MDSCs and lung cancer cells by combination therapy can inhibit IDO signaling and tumor cell proliferation pathways, while reducing T cell exhaustion and promoting enhanced glycolytic metabolism of cytotoxic CD8+ T cells. Here, IDO1 is linked to lung cancer.